Statement updating details on testing of IDenta-Alert explosive detectors released

NewsGuard 100/100 Score

International drug & explosives detection firm IDenta Corp. (PINKSHEETS: IDTA) releases statement updating details about US Department of Defense testing of the IDenta-Alert explosive detectors.

The Department of Defense (DOD), which has started recently to test the Identa Alert Explosive Detectors, is being conducted by the following divisions: Explosive Detection Equipment Program and Trace & Semi-Bulk Project from:

Naveodtechdiv 2008 Stump Neck Road Indian Head, MD 20604

NAVEODTECHDIV is the DOD center of knowledge and expertise on all explosive threats. The command specializes in the following EOD (Explosive Ordnance Disposal) focused areas:

Counter-explosive hazard research, development, testing & evaluation (RDT&E) Special tools and equipment development for detection and defeat Comprehensive threat database tactics, techniques, and procedures development Real-time technical support to EOD responders Counter-explosive hazard technology development and technical expertise to support designated responders http://www.dcmilitary.com/special_sections/sw/030308_IH/ss_153626_31947.shtml http://www.navsea.navy.mil/nswc/eodtechdiv/default.aspx

It should be noted since Identa Corp is in the remaining 5 companies being tested, their products will be available to be purchased by all US Government personnel and military and the test results will help to guide each agency in their purchases.

IDenta Corp. CEO Yaacov Shoham recently stated, "I expect the results of the IDenta testing to be very favorable."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.